Background: For the development of PGRMC1, a multifunctional receptor belonging to membrane-associated progesterone receptor proteins (MAPR) family, as possible predictive marker for increased hormone-dependent breast cancer (BC) risk, a systematic research program has been performed, starting with different BC cells, continued with animal studies and finally with clinical studies with BC patients. Summary: In vitro studies showed dose- and time-dependent BC cell proliferations with all available synthetic progestogens (not with progesterone), but mostly significant only in the presence of PGRMC1. Different animal (xenograft) studies confirmed that synthetic progestogens, but not progesterone and dydrogesterone, increased the estradiol-induced tumor proliferation, although with dydrogesterone, a small time-dependent increase could be seen. Clinical studies with hormone replacement therapy (HRT) to confirm these results are still running. In patients with BC expression of PGRMC1 in BC tissue was correlated to tumor characteristics like diameter, grade, and metastatic status. BC patients with PGRMC1 in the tumors had poorer disease-free and overall survival. After developing of an assay, blood levels could be correlated to the expression in BC tissue showing PGRMC1 superior to tumor markers such as CEA, CA125, CA153, and TPS. Key Messages: This review is summarizing two different functions of PGRMC1: (1) to predict the prognosis of BC patients, already well demonstrated in BC patients and (2) being a possible predictive marker for BC risk during HRT as suggested from in vitro and animal research.

Keywords:
PGRMC1, Breast cancer risk, Progestogens, Hormone replacement therapy, Tumor markers
1.
Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108.411 women without breast cancer. Lancet. 1997;350(9084):1047–59.
2.
Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–33.
3.
Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA. 2004;291(14):701–12.
4.
Collaborative Group on Hormonal Factors in breast Cancer. Type and timing of hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet. 2019;394(1024):1159–1168.
5.
Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2008;107(1):103–11.
6.
Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estradiol-progestogen therapy. Obstet Gynecol. 2009;113(1):65–73.
7.
Schneider C, Jick SS, Meier CR. Risk of gynecological cancers in users of estradiol/dydrogesterone or other HRT preparations. Climacteric. 2009;12:514–24.
8.
Mueck AO, Seeger H, Shapiro S. Risk of breast cancer during hormone replacement therapy: mechanisms. Horm Mol Biol Clin Investig. 2010;3(1):329–39.
9.
Stevenson JC, Farmer RDT. HRT and breast cancer: a million women ride again. Climacteric. 2020;23(3):226–8.
10.
Cahill MA. Progesterone receptor membrane component 1: an integrative review. J Steroid Biochem Mol Biol. 2007;105(1–5):16–36.
11.
Neubauer H, Adam G, Seeger H, Mueck AO, Solomayer E, Wallwiener D, et al. Membrane-initiated effects of progesterone on proliferation and activation of VEGF in breast cancer cells. Climacteric. 2009;12(3):230–9.
12.
Neubauer H, Yang Y, Seeger H, Fehm T, Cahill MA, Tong X, et al. The presence of a membrane-bound progesterone receptor sensitizes the estradiol-induced effect on the proliferation of human breast cancer cells. Menopause. 2011;18(8):845–50.
13.
Stanczyk FZ. Can the increase in breast cancer observed in the estrogen plus progestin arm of the Women’s Health Initiative trial be explained by progesterone receptor membrane component 1?. Menopause. 2011;18(8):833–4.
14.
Lippert C, Seeger H, Wallwiener D, Mueck AO. The effect of medroxyprogesterone acetate and norethisterone on the estradiol stimulated proliferation in MCF-7 cells: comparison of continuous combined versus sequential combined estradiol/progestin treatment. Eur J Gynaecol Oncol. 2001;22(5):331–5.
15.
Mueck AO, Ruan X, Seeger H, Fehm T, Neubauer H. Genomic and non-genomic actions of progestogens in the breast. J Steroid Biochem Mol Biol. 2014;142:62–7.
16.
Seeger H, Wallwiener D, Mueck AO. Influence of stroma-derived growth factors on the estradiol-stimulated proliferation of human breast cancer cells. Eur J Gynaecol Oncol. 2004;25(2):175–7.
17.
Krämer EA, Seeger H, Krämer B, Wallwiener D, Mueck AO. The effects of progesterone, medroxyprogesterone acetate, and norethisterone on growth factor-and estradiol-treated human cancerous and noncancerous breast cells. Menopause. 2005;12(4):468–74.
18.
Zhou J, Yu Q, Chen R, Seeger H, Fehm T, Cahill MA, et al. Medroxyprogesterone acetate- driven increase in breast cancer risk might be mediated via cross-talk with growth factors in the presence of progesterone receptor membrane component-1. Maturitas. 2013;76(2):129–33.
19.
Losel RM, Besong D, Peluso JJ, Wehling M. Progesterone receptor membrane component 1-many tasks for a versatile protein. Steroids. 2008;73(9–10):929–34.
20.
Crudden G, Loesel R, Craven RJ. Overexpression of the cytochrome p450 activator hpr6 (heme-1 domain protein/human progesterone receptor) in tumors. Tumor Biol. 2005;26(3):142–6.
21.
Neubauer H, Ma Q, Zhou J, Yu Q, Ruan X, Seeger H, et al. Possible role of PGRMC1 in breast cancer development. Climacteric. 2013;16(5):509–13.
22.
Ahmed IS, Rohe HJ, Twist KE, Mattingly MN, Craven RJ. Progesterone receptor membrane component 1 (Pgrmc1): a heme-1 domain protein that promotes tumorigenesis and is inhibited by a small molecule. J Pharmacol Exp Ther. 2010;333(2):564–73.
23.
Yu S, Kim T, Yoo KH, Kang K. The T47D cell line is an ideal experimental model to elucidate the progesterone-specific effects of a luminal A subtype of breast cancer. Biochem Biophys Res Commun. 2017;486(3):752–8.
24.
Ruan X, Neubauer H, Yang Y, Schneck H, Schultz S, Fehm T, et al. Progestogens and membrane-initiated effects on the proliferation of human breast cancer cells. Climacteric. 2012;15(5):467–72.
25.
Ruan X, Schultz S, Schneck H, Fehm T, Cahill MA, Seeger H, et al. Nomegestrol acetate sequentially or continuously combined to estradiol did not negatively affect membrane-receptor associated progestogenic effects in human breast cancer cells. Gynecol Endocrinol 2012;28(11):863–6.
26.
Schneck H, Ruan X, Seeger H, Cahill MA, Fehm T, Mueck AO. Membrane-receptor initiated proliferative effects of dienogest in human breast cancer cells. Gynecol Endocrinol. 2013;29(2):160–3.
27.
Neubauer H, Ruan X, Schneck H, Seeger H, Cahill MA, Liang Y, et al. Overexpression of progesterone receptor membrane component 1: possible mechanism for increased breast cancer risk with norethisterone in hormone therapy. Menopause. 2013;20(5):504–10.
28.
Ruan X, Gu M, Cai G, Zhao Y, Wang L, Li X. Progestogens and PGRMC1-dependent breast cancer tumor growth: An in-vitro and xenograft study. Maturitas. 2019;123:1–8.
29.
Fournier A, Fabre A, Mesrine S, Boutron-Ruault MC, Berrino F, Clavel-Chapelon F. Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor–defined invasive breast cancer. J Clin Oncol. 2008;26(8):1260–8.
30.
Bakken K, Fournier A, Lund E, Waaseth M, Dumeaux V, Clavel-Chapelon F, et al. Menopausal hormone therapy and breast cancer risk: impact of different treatments. The European prospective investigation into cancer and nutrition. Int J Cancer. 2011;128(1):144–56.
31.
Zhao Y, Ruan X, Wang H, Li X, Gu M, Wang L, et al. The presence of a membrane-bound progesterone receptor induces growth of breast cancer with norethisterone but not with progesterone: a xenograft model. Maturitas. 2017;102:26–33.
32.
Cai G, Ruan X, Gu M, Zhao Y, Wang Y, Mueck AO. PGRMC1 in animal breast cancer tissue and blood is associated with increased tumor growth with norethisterone in contrast to progesterone and dydrogesterone: four-arm randomized placebo-controlled xenograft study. Gynecol Endocrinol. 2020;36(11):1024–7.
33.
Ruan X, Zhang Y, Mueck AO, Willibald M, Seeger H, Fehm T, et al. Increased expression of progesterone receptor membrane component 1 is associated with aggressive phenotype and poor prognosis in ER-positive and negative breast cancer. Menopause. 2017;24(2):203–9.
34.
Ruan X, Cai G, Wei Y, Gu M, Zhang Y, Zhao Y, et al. Association of circulating progesterone receptor membrane component-1 (PGRMC1) with breast tumor characteristics and comparison with known tumor markers. Menopause. 2020;27(2):183–93.
35.
Cai G, Yang, X, Ruan X, Wang J, Fang Y, Wei Y, et al. Association of circulating progesterone receptor membrane component-1(PGRMC1) with PGRMC1 expression in breast tumour tissue and with clinical breast tumour characteristics. Maturitas. 2020;140:64–71.
36.
Willibald M, Bayer G, Stahlhut V, Poschmann G, Stuhler K, Gierke B, et al. Progesterone receptor membrane component 1 is phosphorylated upon progestin treatment in breast cancer cells. Oncotarget. 2017;8(42):72480–93.
37.
Zhang L, Ruan X, Gu M, Mueck AO. E2 + norethisterone promotes the PI3K–AKT pathway via PGRMC1 to induce breast cancer cell proliferation. Climacteric. 2022;25(5):467–75.
38.
Pedroza DA, Rajamanickam V, Subramani R, Bencomo A, Galvez A, Lakshmanaswamy R. Progesterone receptor membrane component 1 promotes the growth of breast cancers by altering the phosphoproteome and augmenting EGFR/PI3K/AKT signalling. Br J Cancer. 2020;123(8):1326–35.
39.
Pedroza DA, Subramani R, Tiula K, Do A, Rashiraj N, Galvez A, et al. Crosstalk between progesterone receptor membrane component 1 and estrogen receptor α promotes breast cancer cell proliferation. Lab Invest. 2021;101(6):733–44.
40.
Bai Y, Ludescher M, Poschmann G, Stuhler K, Wyrich M, Oles J, et al. PGRMC1 promotes progestin-dependent proliferation of breast cancer cells by binding prohibitins resulting in activation of ERα signaling. Cancers. 2021;13(22):5635.
41.
Gu M, Wang L, Yang C, Li X, Jia C, Croteau S, et al. Micro-RNA-181a suppresses progestin-promoted breast cancer cell growth. Maturitas. 2018;114:60–6.
42.
Asperger H, Stamm N, Gierke B, Pawlak M, Hofmann U, Zanger UM, et al. Progesterone receptor membrane component 1 regulates lipid homeostasis and drives oncogenic signaling resulting in breast cancer progression. Breast Cancer Res. 2020;22:75.
43.
Willibald M, Wurster I, Meisner C, Vogel U, Seeger H, Mueck A, et al. High level of progesteron receptor membrane component 1 (PGRMC 1) in tissue of breast cancer patients is associated with worse response to anthracycline-based neoadjuvant therapy. Horm Metab Res. 2017;49(8):595–603.
44.
Schuster J, Karlsson T, Karlström PO, Poromaa IS, Dahl N. Down-regulation of progesterone receptor membrane component 1 (PGRMC1) in peripheral nucleated blood cells associated with premature ovarian failure (POF) and polycystic ovary syndrome (PCOS). Reprod Biol Endocrinol. 2010;8:58. http://www.rbej.com/content/8/1/58.
45.
Xu X, Ruan X, Ju R, Wang Z, Yang Y, Cheng J, et al. Progesterone receptor membrane component-1 may promote survival of human brain microvascular endothelial cells in Alzheimer’s disease. Am J Alzheimers Dis Other Dementias. 2022;37:1–9.
© 2022 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2022
You do not currently have access to this content.